Amphastar Pharmaceuticals (AMPH) Net Cash Flow (2013 - 2026)

Amphastar Pharmaceuticals has reported Net Cash Flow for 14 years, with the latest figure at $52.7 million in Q2 2026.

• On a quarterly basis, Net Cash Flow rose 1005.12% year-over-year to $52.7 million in Q2 2026; TTM through Jun 2026 was $36.1 million, a 1805.91% increase from a year earlier, with the FY2025 full-year figure at $18.4 million, up 144.68% from the prior year.
• Net Cash Flow was $52.7 million for Q2 2026 at Amphastar Pharmaceuticals, up from $900000.0 in the prior quarter.
• The five-year high for Net Cash Flow was $119.8 million in Q3 2023, with the low at -$126.3 million in Q4 2023.
• Average Net Cash Flow over 5 years is $5.4 million, with a median of $1.7 million recorded in 2024.
• The largest YoY upside for Net Cash Flow was 1459.14% in 2023 against a maximum downside of 10738.45% in 2023.
• Over 5 years, Net Cash Flow stood at -$1.2 million in 2022, then sank by 10738.45% to -$126.3 million in 2023, then surged by 67.93% to -$40.5 million in 2024, then fell by 13.79% to -$46.1 million in 2025, then soared by 214.28% to $52.7 million in 2026.
• The last three Net Cash Flow figures came in at $52.7 million (Q2 2026), $900000.0 (Q1 2026), and -$46.1 million (Q4 2025), per Business Quant data.